Q2 2021 13F Holders as of 30 Jun 2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
226,220,429
-
Total 13F shares
-
86,300,061
-
Share change
-
-2,028,305
-
Total reported value
-
$2,250,274,646
-
Put/Call ratio
-
99%
-
Price per share
-
$26.08
-
Number of holders
-
178
-
Value change
-
-$84,501,881
-
Number of buys
-
119
-
Number of sells
-
55
Institutional Holders of Allogene Therapeutics, Inc. - Common Stock (ALLO) as of Q2 2021
As of 30 Jun 2021,
Allogene Therapeutics, Inc. - Common Stock (ALLO) was held by
178 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
86,300,061 shares.
The largest 10 holders included
TPG Group Holdings (SBS) Advisors, Inc., BlackRock Inc., VANGUARD GROUP INC, Capital Research Global Investors, PRIMECAP MANAGEMENT CO/CA/, PRICE T ROWE ASSOCIATES INC /MD/, Capital International Investors, ALLIANCEBERNSTEIN L.P., STATE STREET CORP, and JPMORGAN CHASE & CO.
This page lists
179
institutional shareholders reporting positions in this security
for the Q2 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.